Timothy Juday

684 total citations
43 papers, 543 citations indexed

About

Timothy Juday is a scholar working on Infectious Diseases, Epidemiology and Hepatology. According to data from OpenAlex, Timothy Juday has authored 43 papers receiving a total of 543 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Infectious Diseases, 18 papers in Epidemiology and 14 papers in Hepatology. Recurrent topics in Timothy Juday's work include HIV/AIDS Research and Interventions (26 papers), HIV/AIDS drug development and treatment (24 papers) and Hepatitis C virus research (14 papers). Timothy Juday is often cited by papers focused on HIV/AIDS Research and Interventions (26 papers), HIV/AIDS drug development and treatment (24 papers) and Hepatitis C virus research (14 papers). Timothy Juday collaborates with scholars based in United States, Germany and United Kingdom. Timothy Juday's co-authors include Daniel Seekins, Dana P. Goldman, Sammy Saab, Lisa Rosenblatt, P. Hines, Ivy Tonnu-Mihara, Jeffrey S. McCombs, Yong Yuan, Gilbert L’Italien and Edward Kim and has published in prestigious journals such as Gastroenterology, PLoS ONE and Journal of Hepatology.

In The Last Decade

Timothy Juday

42 papers receiving 526 citations

Peers

Timothy Juday

EPIDE

HEPAT

VIROL

Nikoloz Chkhartishvili Georgia

Bharat Bhushan Rewari India

Cristiana Oprea Romania

Nicolas Durier Thailand

Aristophane Tanon Ivory Coast

Franziska Schoeni‐Affolter Switzerland

Ángeles Castro‐Iglesias Spain

Jennifer Y. Chen United States

Lali Sharvadze Georgia

Benjamin Eckhardt United States

Nikoloz Chkhartishvili Georgia

Timothy Juday

358 ×1.2

EPIDE

255 ×0.8

223 ×1.1

HEPAT

75 ×0.9

VIROL

38 ×0.4

Citations per year, relative to Timothy Juday Timothy Juday (= 1×) peers Nikoloz Chkhartishvili

Countries citing papers authored by Timothy Juday

Since Specialization

Citations

This map shows the geographic impact of Timothy Juday's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy Juday with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy Juday more than expected).

Fields of papers citing papers by Timothy Juday

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy Juday. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy Juday. The network helps show where Timothy Juday may publish in the future.

Co-authorship network of co-authors of Timothy Juday

This figure shows the co-authorship network connecting the top 25 collaborators of Timothy Juday. A scholar is included among the top collaborators of Timothy Juday based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timothy Juday. Timothy Juday is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Drozd, Daniel R., Michael S. Saag, Andrew O. Westfall, et al.. (2017). Comparative effectiveness of single versus multiple tablet antiretroviral therapy regimens in clinical HIV practice. Medicine. 96(14). e6275–e6275. 4 indexed citations

Huber, Caroline, Mark T. Linthicum, Timothy Juday, et al.. (2016). Costs and spillover effects of private insurers' coverage of hepatitis C treatment.. PubMed. 22(6 Spec No.). SP236–44. 5 indexed citations

Linthicum, Mark T., Yuri Sánchez González, Timothy Juday, et al.. (2016). Value of expanding HCV screening and treatment policies in the United States.. PubMed. 22(6 Spec No.). SP227–35. 20 indexed citations

Saab, Sammy, Hélène Parisé, Scott J. Johnson, et al.. (2016). Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States. Advances in Therapy. 33(8). 1316–1330. 9 indexed citations

Bernstein, David, et al.. (2015). Ribavirin does not impact health-related quality of life (HRQOL) in patients on Ombitasvir/ Paritaprevir /Ritonavir and dasabuvir at the end of 12-week treatment in Treatment-NaÏve adults with Genotype 1A (GT1A) Chronic Hepatitis C. Value in Health. 18(3). A227–A227. 2 indexed citations

Johnson, Scott J., et al.. (2015). Long-term cost per sustained virologic response in patients with Genotype 1 Chronic Hepatitis C virus treated with Viekira Pak +/- Ribavirin and standard of care in the US. Value in Health. 18(3). A226–A226. 1 indexed citations

Johnson, Steven W., Hélène Parisé, Timothy Juday, et al.. (2015). Cost-effectiveness of treating Hepatitis C Virus (HCV) Genotype 1 (GT1) patients with abbvie 3D (Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir) +/- ribavirin compared to harvoni (Sofosbuvir/Ledipasvir) in the United States. Value in Health. 18(3). A225–A225. 1 indexed citations

Cure, S., et al.. (2015). Systematic Literature Review and Meta-Analysis of Renal Function in Human Immunodeficiency Virus (HIV)-Infected Patients Treated with Atazanavir (ATV)-Based Regimens. PLoS ONE. 10(5). e0124666–e0124666. 7 indexed citations

Johnston, Stephen S., Timothy Juday, Amanda M. Farr, Bong-Chul Chu, & Tony Hebden. (2014). Comparison between guideline-preferred and nonpreferred first-line HIV antiretroviral therapy.. PubMed. 20(6). 448–55. 3 indexed citations

10.

Bonafede, Machaon, et al.. (2013). Cost-Effectiveness Of Efavirenz Compared With Generic Nevirapine In Hiv Patients Initiating First-Line Treatment In The United States. Value in Health. 16(3). A92–A92.

11.

Juday, Timothy, et al.. (2013). Cost-Effectiveness Of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Compared With Efavirenz/Emtricitabine/Tenofovir As First-Line Hiv Antiretroviral Therapy In The Adult Population In The United States. Value in Health. 16(3). A92–A92. 2 indexed citations

12.

Bonafede, Machaon, et al.. (2013). Cost-effectiveness of efavirenz vs rilpivirine in HIV patients initiating first-line combination antiretroviral therapy. Journal of Medical Economics. 16(4). 552–559. 3 indexed citations

13.

Johnston, Stephen S., Timothy Juday, Derek Espindle, et al.. (2013). Comparative Incidence and Health Care Costs of Medically Attended Adverse Effects among U.S. Medicaid HIV Patients on Atazanavir- or Darunavir-Based Antiretroviral Therapy. Value in Health. 16(2). 418–425. 7 indexed citations

14.

Broder, Michael S., et al.. (2013). Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US. ClinicoEconomics and Outcomes Research. 5. 437–437. 12 indexed citations

15.

Napravnik, Sonia, Joseph J. Eron, Timothy R. Sterling, et al.. (2012). Outcomes of Second Combination Antiretroviral Therapy Regimens Among HIV-Infected Persons in Clinical Care: A Multicenter Cohort Study. AIDS Research and Human Retroviruses. 29(3). 574–580. 9 indexed citations

16.

Johnston, Stephen S., Timothy Juday, Daniel Seekins, Derek Espindle, & Bong-Chul Chu. (2012). Association Between Prescription Cost Sharing and Adherence to Initial Combination Antiretroviral Therapy in Commercially Insured Antiretroviral-Naïve Patients with HIV. Journal of Managed Care Pharmacy. 18(2). 129–145. 17 indexed citations

17.

Willig, James H., Andrew O. Westfall, Michael J. Mugavero, et al.. (2012). Effect of Persistency of First-Line HIV Antiretroviral Therapy on Clinical Outcomes. AIDS Research and Human Retroviruses. 29(4). 698–703. 4 indexed citations

18.

Juday, Timothy, et al.. (2011). Factors Associated with Complete Adherence to HIV Combination Antiretroviral Therapy. HIV Clinical Trials. 12(2). 71–78. 52 indexed citations

19.

Broder, Michael S., Eunice Chang, Tanya G. K. Bentley, Timothy Juday, & Jonathan Uy. (2011). Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States. Journal of Medical Economics. 14(2). 167–178. 10 indexed citations

20.

Juday, Timothy, Hong Tang, Melissa Harris, et al.. (2010). Adherence to Chronic Hepatitis B Treatment Guideline Recommendations for Laboratory Monitoring of Patients Who Are Not Receiving Antiviral Treatment. Journal of General Internal Medicine. 26(3). 239–244. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact